Sugarloaf Wealth Management’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Sugarloaf Wealth Management’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-213	Closed	-$5.36K	–	744
2022 Q4	$5.36K	Sell	213 -98	-32%	-$2.63K	﹤0.01%	572
2022 Q3	$9K	Hold	311	–	–	﹤0.01%	538
2022 Q2	$9K	Hold	311	–	–	﹤0.01%	537
2022 Q1	$11K	Hold	311	–	–	﹤0.01%	483
2021 Q4	$14K	Hold	311	–	–	﹤0.01%	475
2021 Q3	$16K	Hold	311	–	–	﹤0.01%	462
2021 Q2	$16K	Sell	311 -2,108	-87%	-$98.9K	﹤0.01%	449
2021 Q1	$14	Buy	2,419 +1,669	+223%	+$81.5K	﹤0.01%	467
2020 Q4	$32K	Buy	750 +375	+100%	+$16.2K	0.01%	308
2020 Q3	$15K	Hold	375	–	–	0.01%	400
2020 Q2	$14K	Buy	+375	New	+$12.7K	0.01%	403

Other funds holding IDNA

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WAP

Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Sugarloaf Wealth Management's IDNA Position: Q1 2023 in Review

Sugarloaf Wealth Management sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q1 2023, closing a stake of 213 shares — an estimated $5.36K sold.

Sugarloaf Wealth Management first reported a position in IDNA in Q2 2020 and held it in 11 quarters. The position peaked at $32K in Q4 2020. 75 funds tracked by Wall St. Rank hold IDNA as of Q1 2023.

Sugarloaf Wealth Management reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q1 2023 after selling out during the quarter.
Sugarloaf Wealth Management sold 213 iShares Genomics Immunology and Healthcare ETF shares in Q1 2023, an estimated $5.36K.
Sugarloaf Wealth Management first reported a position in iShares Genomics Immunology and Healthcare ETF in Q2 2020 and held it in 11 quarters.
Sugarloaf Wealth Management's iShares Genomics Immunology and Healthcare ETF position peaked at $32K in Q4 2020.
75 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q1 2023.

Based on Sugarloaf Wealth Management's 13F filing for Q1 2023, filed 26 Apr 2023.